H.C. Wainwright Lifts PT on BioCryst Pharmaceuticals (BCRX) to $32 From $30

Core Viewpoint - BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) is highlighted as a promising small-cap stock with significant upside potential, particularly following the FDA approval of Orladeyo for pediatric patients with hereditary angioedema [1][2]. Group 1: FDA Approval and Product Details - On December 12, BioCryst Pharmaceuticals announced that the FDA approved its New Drug Application for an oral pellet formulation of ORLADEYO (berotralstat) for pediatric patients aged 2 to <12 years with hereditary angioedema [2]. - ORLADEYO is noted as the first and only targeted oral prophylactic therapy for this age group, which previously had limited treatment options that were burdensome [2]. - The company also reported that a capsule formulation of ORLADEYO was approved in December 2020 for patients aged 12 years and older, and it is now approved in over 45 countries [3]. Group 2: Investment Outlook - H.C. Wainwright raised the price target for BioCryst Pharmaceuticals from $30 to $32 and reaffirmed a Buy rating, citing the approval of Orladeyo as a significant factor for this update [1]. - The company is recognized for its innovative approach in biotechnology, focusing on structure-guided drug design to develop therapies for rare diseases [3].